Archive · 17 Dec 2025
Decode Age Secures ₹14.48 Crore in Pre-Series A Funding
Decode Age is a company that studies how people age and how their gut bacteria affect their health.
They just got ₹14.48 crore from an investor named Krishna Prasad Chigurupati to help them do more research.
This money will help them understand how our bodies age and how gut bacteria can influence our health.
They want to make this information easy for people to understand and use.
Decode Age has special labs where they study tiny parts of our bodies, like DNA and bacteria, to find out how to help people stay healthy as they get older.
They also make special supplements based on their research.
The company started in 2021 and is working on some of the most advanced ways to study gut bacteria and how it affects our health.
Decode Age raised ₹14.48 crore in Pre-Series A funding led by Krishna Prasad Chigurupati.
The company focuses on ageing biology, biomarker research, and gut microbiome science.
The investment will support advanced research, biomarker programs, and the development of a microbiome-centred longevity ecosystem.
Decode Age has developed a comprehensive longevity research platform including multi-omics testing and precision-based interventions.
The company aims to provide practical tools for healthy ageing and insights into conditions like cancer and dementia.
- Who
- Decode Age, a longevity science organization, led by CEO and Co-founder Parth Amin, and investor Krishna Prasad Chigurupati, Chairman and Managing Director of Granules India Limited.
- What
- Decode Age has raised ₹14.48 crore in Pre-Series A funding to advance its mission in ageing biology and gut microbiome research.
- When
- The funding was announced on December 17, 2025.
- Where
- The company is based in India, with advanced metagenomics and microbiome laboratories.
- Why
- The investment aims to strengthen Decode Age's research in ageing biology, expand biomarker programs, and develop a microbiome-centred longevity ecosystem.
- Company
- Decode Age
- Funding Amount
- ₹14.48 crore
- Funding Round
- Pre-Series A
- Lead Investor
- Krishna Prasad Chigurupati
- Company Focus
- Longevity science, ageing biology, gut microbiome research
- Year Founded
- 2021
- Key Technologies
- Multi-omics testing, biomarker discovery, precision-based interventions
- CEO and Co-founder
- Parth Amin